Andrew Bohm, M.D., chief strategist at Pfizer, is leaving his position two years after joining the New York drugmaker after…

AstraZeneca’s Ultomiris, already approved for the treatment of four rare diseases, has also shown potential in another rare disease, IgA…

WASHINGTON – The Trump administration will ask states to create new plans to verify health care workers paid by federally…

Researchers have developed a powerful new imaging technique that reveals ultrafast phenomena in the microscopic world in far more detail…

After winning two clinical trials for intractable and early-stage kidney cancer, Merck & Co.’s blockbuster candidate Wellireg surprisingly failed to…